

Role of Clinical Pharmacists During Cardiopulmonary Resuscitation in Intensive Care Units and Emergency Departments: A Narrative Review

Asad Jamal Ansari^{1*}, Saurabh Kumar Chauhan²

Abstract

Cardiopulmonary resuscitation (CPR) represents an essential emergency procedure designed to reestablish spontaneous circulation and enhance survival rates among individuals suffering cardiac arrest. Successful resuscitation necessitates prompt clinical judgment, expeditious pharmaceutical interventions, compliance with advanced cardiovascular life support (ACLS) guidelines, and synchronized interprofessional collaboration. During recent decades, clinical pharmacists have gained greater incorporation within emergency response and resuscitation units owing to their specialized knowledge in medication oversight, pharmacotherapeutic enhancement, and patient protection. This narrative examination consolidates existing evidence concerning clinical pharmacist involvement during CPR within intensive care environments and emergency medicine departments. Clinical pharmacists provide substantial contributions through pharmaceutical preparation and delivery, dosage confirmation, treatment guidance, medication safety surveillance, and enhancement of time-sensitive therapeutic interventions throughout resuscitation procedures. Their involvement has demonstrated associations with improved ACLS protocol compliance, decreased pharmaceutical errors, strengthened interprofessional communication, and enhanced emergency medication distribution efficiency. Pharmacists additionally fulfil crucial functions in post-arrest management via hemodynamic assessment, pharmacotherapeutic enhancement, and detection of drug-related complications in critically ill individuals. Furthermore, educational initiatives, simulation-based learning, ACLS and basic life support (BLS) credentialing, and interdisciplinary partnerships remain vital for sustaining pharmacist proficiency in emergency response situations. Although pharmacist recognition within resuscitation teams continues expanding, obstacles such as insufficient personnel, training inconsistencies, absence of uniform role specifications, and limited data regarding extended clinical results persist in influencing their incorporation into emergency medical services. Prospective investigations emphasizing standardized practice models and extended clinical outcomes may additionally reinforce clinical pharmacist contributions to cardiopulmonary resuscitation and critical care administration.

*Author for Correspondence

Asad Jamal Ansari

E-mail: asadjamalansari786@gmail.com

¹Lecturer, Faculty of Pharmacy, Integral University, Lucknow, Uttar Pradesh, India

²Researcher, Department of Pharmacology, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi, India

Received Date: May 10, 2026

Accepted Date: May 12, 2026

Published Date: May 30, 2026

Citation: Asad Jamal Ansari, Saurabh Kumar Chauhan. Role of Clinical Pharmacists During Cardiopulmonary Resuscitation in Intensive Care Units and Emergency Departments: A Narrative Review. International Journal of Emergency and Trauma Nursing and Practices. 2026; 4(1): 12–25p.

Keywords: Cardiopulmonary resuscitation, clinical pharmacist, cardiac arrest, advanced cardiovascular life support, emergency medicine, medication safety

INTRODUCTION

In North America and around the world, clinical pharmacists have been identified as a valued and essential part of cardiac arrest and emergency trauma teams in the past decade. This recognition is

based on an increasing body of evidence of their clinical efficacy and usefulness, as well as organizational endorsement (such as by the American College of Emergency Physicians), and greater integration into advanced cardiovascular life support (ACLS)-certified resuscitation teams [1–6]. In many hospitals, clinical pharmacists have come to be part of the emergency response team and play a role in decision-making and medication management during high-acuity events. The existing literature indicates that pharmacist participation in emergency response teams results in fewer medication errors, increased adherence to ACLS protocols, shorter time to medication administration, and possible cost savings for institutions [7, 8]. They are involved in various essential tasks, such as drug preparation and administration, drug information provision, therapeutic recommendations, and documentation support [7–9]. The time to analgesia during resuscitation and other time-critical therapies can be shortened by pharmacists in several observational studies, as can be the number of medication errors, compliance with a protocol, and closed-loop communication among a multidisciplinary team [10–12]. However, the effects of pharmacist participation on the effectiveness of medication and clinical outcomes (such as length of stay, morbidity, and mortality) in cardiac resuscitation teams are not well known [13–15]. This knowledge of the scope of the services might contribute to defining a more defined role for clinical pharmacists participating in emergency response and resuscitation teams. The multidisciplinary approach is crucial to the success of resuscitation in cardiac arrest, due to the complexity and urgency of the management needed. In-hospital cardiac arrest (IHCA) is a serious threat to cardiovascular health and affects more than 290,000 people in the United States annually [16, 17]. IHCA survival rates have improved in the last decade [18–22] with better acute resuscitation survival (return of spontaneous circulation (ROSC)). But in those who survive a cardiac arrest, the morbidity and mortality rate is still high, resulting in a significant proportion of patients enduring neurological, functional, and psychiatric disability [19, 21–23]. The focus of the work on improving IHCA outcomes has largely centered on acute resuscitation efforts, while efforts to understand and improve post-resuscitation care are less intensive [24]. Highlighting this, the American Heart Association (AHA) Get With The Guidelines® Resuscitation (GWTG®-R) Hospital Recognition Criteria only include intra-arrest benchmarks [25, 26]. Thus, the purpose of this narrative review is to describe the current evidence of the clinical pharmacist's role during CPR in the ED and the ICU with a specific focus on medication safety, compliance, pharmacotherapeutic management, and outcomes.

OVERVIEW OF CARDIAC ARREST AND CARDIOPULMONARY RESUSCITATION

A researcher [3] introduced the concept of post-cardiac arrest syndrome, encompassing (1) cerebral injury following cardiac arrest, (2) myocardial dysfunction after cardiac arrest, (3) systemic ischemia/reperfusion phenomena, and (4) ongoing precipitating pathology. This syndrome encompasses neurological damage, cardiac dysfunction, systemic ischemia-reperfusion trauma, and continuing underlying pathology following successful revival.

Individuals who survive cardiac arrest may experience various systemic complications, such as pulmonary failure, kidney impairment, circulatory shock, and bleeding disorders [4].

Pathophysiology of Cardiac Arrest

Post-cardiac arrest syndrome represents a constellation of pathophysiological mechanisms encompassing (1) cerebral injury, (2) myocardial dysfunction, and (3) systemic ischemia/reperfusion phenomena [6]. While extended whole-body ischemia initially produces widespread tissue and organ damage, further injury develops during and after reperfusion [7, 8]. Neurological damage after cardiac arrest occurs predominantly through ischemia-reperfusion injury and inflammatory mechanisms [9]. In addition to the cerebral tissue, the heart also sustains ischemic damage. Cardiac dysfunction is a frequent cause of early death following cardiac arrest and temporary global impairment. Ischemia/reperfusion triggers widespread activation of the immune and coagulation systems, elevating the likelihood of multi-organ failure and infectious complications [9].

Cardiopulmonary Resuscitation and ACLS

Guidelines recommend norepinephrine as the primary vasopressor agent because of its association with reduced mortality, decreased risk of major complications, and fewer cardiac rhythm disturbances than those associated with dopamine.

ACLS encompasses the prompt identification of cardiac arrest, superior CPR quality, appropriate defibrillation timing, airway control, and suitable medication administration [10].

Return of Spontaneous Circulation

Survival rates for IHCA have improved over the previous decade [18–20], primarily attributable to enhanced acute resuscitation success rates (specifically increased ROSC). Nevertheless, among initial cardiac arrest survivors, post-arrest morbidity and mortality continue to be elevated, with numerous patients experiencing persistent neurological, functional, and psychological impairments [21–23]. Initiatives to enhance IHCA outcomes have predominantly concentrated on acute resuscitation procedures, with reduced emphasis on understanding and advancing post-resuscitation management [24]. Notwithstanding improved ROSC rates, post-resuscitation morbidity and mortality persist at considerable levels.

Importance of Multidisciplinary Management

Over the last ten years, clinical pharmacists have gained substantial recognition as essential contributors to cardiac arrest and emergency trauma response teams across North America and internationally. This growing recognition stems from accumulating evidence regarding their clinical contributions, institutional support (such as endorsement from the American College of Emergency Physicians), and enhanced incorporation into ACLS-certified resuscitation units [1–6]. Clinical pharmacists have been systematically incorporated into emergency response teams across numerous healthcare facilities, where they participate in immediate clinical decision-making and pharmaceutical management during critical care situations. Contemporary research indicates that pharmacist participation in emergency response teams results in decreased medication errors, enhanced compliance with ACLS guidelines, reduced medication administration intervals, and possible institutional cost reductions [7, 8]. Their primary responsibilities include medication preparation and delivery, drug information provision, therapeutic guidance, and documentation assistance [7–9]. Multiple observational studies have shown that pharmacists can facilitate reduced time to pain management and other time-sensitive treatments during resuscitation, minimize medication errors, enhance protocol adherence, and facilitate effective closed-loop communication among interdisciplinary teams [10–12]. Nevertheless, the influence of pharmacist participation on medication efficacy and clinical outcomes (such as hospital stay duration, morbidity, and mortality) within cardiac resuscitation teams remains unclear [13–15]. Understanding these contributions could assist in developing a more definitive framework for incorporating clinical pharmacists into emergency response and resuscitation teams.

ROLE OF CLINICAL PHARMACISTS DURING CARDIOPULMONARY RESUSCITATION

Medication Preparation and Administration

Clinical pharmacists play crucial roles in formulating and delivering emergency pharmaceuticals, supplying pharmaceutical knowledge, offering therapeutic guidance, and providing documentation assistance [7–9]. Multiple observational studies have shown that pharmacists can assist in decreasing the time to pain relief and other time-sensitive treatments during resuscitation efforts, minimize pharmaceutical mistakes, enhance protocol adherence, and facilitate closed-loop communication among interdisciplinary teams [10–12].

ACLS Guideline Adherence and Medication Safety

For primary endpoints, most studies documented adherence to ACLS protocols and pharmaceutical errors when comparing the impact of pharmacist presence (PP) versus absence (PA). These surrogate

indicators are significant as ACLS protocol compliance and pharmaceutical precision are directly connected to prompt and suitable resuscitation interventions, which affect patient survival and recovery outcomes. While pharmacist participation enhances various process-oriented results, evidence concerning its direct impact on mortality and extended clinical outcomes remains constrained [27–36].

Pharmacist contributions were particularly evident in cardiac resuscitation versus trauma in terms of ACLS adherence and pharmaceutical errors. Multiple investigations have documented enhanced ACLS protocol compliance when pharmacists are engaged in resuscitation teams. Enhancement of drug formulation and delivery is a fundamental advantage of pharmacist involvement during resuscitation [37, 38]. Various studies have documented improved patterns of pharmaceutical safety and protocol compliance when pharmacists are engaged in resuscitation teams. Activities, including time to drug delivery (such as analgesia and sedation) and emergency resuscitation through pharmacological interventions, represent additional areas where pharmacist participation enhances ACLS protocol adherence [38, 39]. Various investigations have observed that the total quantity of pharmaceutical errors similarly declined when pharmacists were present on the code team [13, 39–41]. This decrease in pharmaceutical errors is essential because mistakes during resuscitation may result in adverse drug reactions, jeopardizing patient safety and clinical results (Table 1).

Participation in Code Blue and Rapid Response Teams

The PPA supports the active engagement of pharmacists in institutional medical emergency team committees and the development of emergency medication kits and resuscitation equipment for use in emergencies. The PPA endorses that all facilities requiring pharmacist involvement in CPR incidents should implement preparatory educational programs. The PPA suggests that pharmacists acquire emergency response credentials, including basic life support (BLS) and pediatric advanced life support, with potential consideration for advanced cardiac life support and neonatal resuscitation program certification based on their specific practice settings. Furthermore, the PPA advises that pharmacists receive education regarding the pharmacotherapy of medications utilized in CPR procedures, encompassing medication preparation and administration protocols, drug compatibility, recommended emergency medication dosing, and knowledge of institutional emergency equipment. The PPA suggests that pharmacy leadership should facilitate the development of training competency programs for all pharmacist personnel engaged in CPR incidents. Such training should encompass educational sessions featuring pediatric case studies, practical simulation-based mock codes for CPR scenarios and typical pediatric medical emergencies, and ongoing educational initiatives. Multiple published studies endorse supplementary pharmacist education beyond the previously mentioned certifications. Machado et al. [42] discovered that pharmacists demonstrated more positive attitudes toward CPR participation when they perceived their training as sufficient. Roddy et al. [43] showed that combined theoretical instruction and pediatric simulation-based education enhanced pharmacists' knowledge and confidence in pediatric emergency response.

Documentation and Clinical Decision Support

Clinical pharmacists also support documentation and clinical decision-making throughout resuscitation by providing drug information, therapeutic guidance, and medication-related assistance to healthcare teams.

PHARMACOTHERAPEUTIC MANAGEMENT DURING CARDIOPULMONARY RESUSCITATION

Vasopressors Used During CPR

Norepinephrine serves as the primary vasopressor since norepinephrine is associated with reduced mortality, diminished risk of significant adverse events, and cardiac arrhythmias. The norepinephrine-dobutamine combination is more efficacious and safer than epinephrine [44]. Vasopressors serve an essential function during cardiopulmonary resuscitation by enhancing coronary and cerebral perfusion pressures and maintaining hemodynamic stability.

Table 1. Role and clinical impact of clinical pharmacists during cardiopulmonary resuscitation.

Clinical pharmacist activity	Role during CPR	Potential clinical impact	Supporting outcome
Medication preparation and administration	Preparation and timely administration of emergency medications, including vasopressors, antiarrhythmics, sedatives, and ACLS drugs	Reduces delay in emergency pharmacotherapy	Improved response time and workflow efficiency
Dose verification and medication safety monitoring	Verification of medication doses, drug compatibility, contraindications, and interactions during resuscitation	Minimize medication-related errors and adverse drug events	Enhanced patient safety
ACLS guideline support	Assistance with evidence-based medication selection and adherence to ACLS algorithms	Improve standardized resuscitation practices	Better ACLS adherence
Participation in code blue and rapid response teams	Active involvement in multidisciplinary emergency response teams during high-acuity situations	Enhance team coordination and communication	Improved multidisciplinary collaboration
Pharmacotherapeutic decision-making	Provision of therapeutic recommendations and drug information during resuscitation	Supports evidence-based emergency pharmacotherapy	Optimized clinical management
Post-cardiac arrest medication management	Monitoring and optimization of vasopressors, antiarrhythmics, sedatives, anticoagulants, and other critical medications following ROSC	Improves post-resuscitation care quality	Better therapeutic monitoring and medication optimization
Documentation and clinical support	Assistance with medication documentation and therapeutic communication during resuscitation	Improves continuity of care and treatment accuracy	Enhanced clinical workflow
Simulation-based training and mock code participation	Participation in emergency preparedness exercises and simulation-based educational programs	Improves pharmacist competency and emergency preparedness	Increased confidence and resuscitation readiness

Antiarrhythmic Agents During Resuscitation

Nevertheless, prophylactic lidocaine administration may be considered for recurring ventricular fibrillation or ventricular tachycardia during transport when contraindications are absent.

Medication Safety and Monitoring During Resuscitation

Although numerous medication orders in the ED qualify under the aforementioned exceptions, the assessment level during medication order evaluation should remain consistent with that provided to patients throughout the hospital. The particular function of an emergency medicine pharmacists (EMP) may not concentrate solely on ED medication order review processes but should instead mirror the role of other pharmacy specialists delivering direct patient care services within the facility [45–48]. Ideally, all orders for high-risk medications should undergo prospective evaluation, but optimal medication utilization in the ED necessitates balancing patient safety assurance with the prevention of care delays. EMPs should implement a triage approach within the medication order review process to prioritize the assessment of high-risk medications, high-risk patient populations, and emergent or urgent circumstances, followed by routine medication orders. When assessing medication orders, EMPs should concentrate on essential elements, including medication and dosage appropriateness, potential drug interactions, and patient-specific considerations [49].

Medication Therapy Monitoring

EMP should provide guidance on monitoring criteria for both therapeutic efficacy and medication safety within emergency department settings. Considering the patient volume in emergency departments and the various demands on EMP' time, emphasis should be placed on high-risk pharmaceutical agents (such as vasopressin, intravenous antihypertensive medications, insulin preparations, pain management and sedation drugs, and antithrombotic and hemostatic medications). EMP must collaborate extensively with nursing personnel and conduct patient reassessments for

individuals receiving these medications to verify appropriate therapeutic responses, safety, and adequate monitoring completion. Where warranted, EMP should communicate with healthcare providers to intensify or reduce care interventions.

The recognition and evaluation of monitoring criteria associated with pharmaceutical therapy are fundamental components of the medication utilization process. These elements establish whether the chosen therapy demonstrated safety and efficacy, proved suboptimal, or was unsuccessful, necessitating modifications to the treatment. Pharmacist involvement in pharmaceutical therapy surveillance enhances clinical outcomes across various healthcare environments, including therapy selection, modification, and monitoring of treatments for chronic conditions, as well as therapeutic drug monitoring for antimicrobial and anticoagulation therapy within hospital environments. These clinical improvements encompass diminished medication errors, decreased adverse event frequencies, enhanced medication compliance, and improved medication appropriateness, with these benefits being applicable to emergency department settings through emergency medicine pharmacist services. EMP should address chronic therapeutic concerns when appropriate [50].

Post-Cardiac Arrest Pharmacology

Circulatory stabilization following the ROSC is crucial for maintaining sufficient tissue perfusion and minimizing secondary organ damage. Vasopressin and inotropic medications, including norepinephrine and dobutamine, are frequently employed to support arterial pressure and cardiac performance.

Antiarrhythmic medications may be necessary following the ROSC to prevent recurring ventricular dysrhythmias and preserve cardiac rhythm stability.

Meticulous oxygenation and respiratory management are critical elements of post-cardiac arrest treatment to minimize neurological damage and sustain appropriate tissue oxygen provision.

Controlled temperature management is routinely implemented following the ROSC to decrease neurological injury and enhance neurological outcomes.

CLINICAL PHARMACIST ROLE IN POST-CARDIAC ARREST CARE

Forward-looking prescription evaluations conducted by EMPs can substantially reduce medication error frequencies. Regardless of the methodology employed to detect medication errors, a considerable percentage of those prevented by EMPs are deemed clinically significant or severe [49, 51].

EMPs must offer guidance regarding surveillance parameters for both the therapeutic efficacy and safety of medications dispensed in the emergency department. Considering the patient volume in the ED and conflicting demands on EMP attention, emphasis should be placed on high-risk pharmaceutical agents (such as vasopressors, intravenous antihypertensive medications, insulin preparations, pain management and sedation drugs, anticoagulants, and hemostatic therapies). EMPs must collaborate closely with nursing personnel and continuously evaluate patients receiving these medications to ensure that appropriate therapeutic responses, safety measures, and monitoring protocols are implemented. When warranted, EMPs should communicate with healthcare providers to intensify or reduce the therapeutic interventions.

EMP enhance post-cardiac arrest care through pharmaceutical surveillance, dosage optimization, therapeutic guidance, and recognition of drug-related complications in critically ill patients [52].

IMPACT OF CLINICAL PHARMACIST PARTICIPATION ON CLINICAL OUTCOMES Reduction in Medication Errors

Medication mistakes during cardiopulmonary resuscitation frequently occur because of the high-pressure and time-critical characteristics of emergency medicine, which typically demands rapid

pharmaceutical preparation, dosage calculations, and delivery of high-alert drugs. Emergency medicine pharmacist engagement during resuscitation has been linked to substantial decreases in drug-related errors through prospective prescription evaluation, dosage confirmation, and ongoing pharmacotherapy surveillance. Pharmacists enhance medication safety by recognizing potential drug interactions, avoiding dosing errors, confirming intravenous medication compatibility, and promoting evidence-based pharmaceutical selection during ACLS. Their participation is especially crucial during the delivery of vasopressor agents, antiarrhythmic medications, sedation drugs, and other high-risk pharmaceuticals frequently used in cardiac arrest treatment. Furthermore, pharmacists support medical teams by delivering immediate therapeutic guidance and ensuring compliance with institutional safety standards. Multiple investigations have shown that pharmacist participation in emergency response and resuscitation teams enhances medication precision, reduces preventable adverse pharmaceutical events, and strengthens overall patient safety during intensive care management [2, 53].

Improvement in ACLS Guideline Adherence

Conformity to ACLS protocols is crucial for enhancing the quality and efficacy of cardiopulmonary resuscitation. Nevertheless, the high-stress environment of cardiac arrest care may increase the probability of protocol variations, delayed medication delivery, and dosing errors [54]. EMP plays an important role in enhancing ACLS protocol compliance by supporting healthcare teams with proper pharmaceutical selection, dosage confirmation, and prompt delivery of emergency medications during resuscitation procedures. Their active engagement during code blue events supports evidence-based pharmacotherapy and encourages adherence to standardized resuscitation guidelines. Various investigations have documented that pharmacist participation during cardiac arrest care improves protocol compliance, strengthens medication delivery precision, and contributes to more coordinated and interdisciplinary resuscitation activities [2].

Optimization of Medication Administration and Response Time

Inadequate educational preparation and limited institutional support may hinder the effective participation of clinical pharmacists in resuscitation teams and emergency response initiatives. Variability in emergency medicine training, insufficient access to simulation-based learning, and minimal participation in practice code scenarios may affect pharmacists' confidence and competence during critical resuscitation events. In some healthcare settings, resource constraints encompassing staffing shortages, lack of structured training initiatives, and limited access to continuous professional education may further restrict the development of emergency preparedness skills among pharmacy practitioners. Additionally, the absence of uniform competency assessment frameworks may lead to disparities in pharmacist performance during cardiac arrest management. Strengthening training curricula, simulation-based education, and collaborative learning experiences may promote enhanced pharmacist preparedness and improve participation in emergency and intensive care settings [55].

Impact on Patient Safety and Clinical Outcomes

The integration of clinical pharmacists into cardiopulmonary resuscitation efforts has been associated with enhanced patient safety outcomes and improved emergency care quality. Pharmacist involvement in resuscitation teams facilitates medication safety through dosage confirmation, mitigation of drug-related adverse events, recognition of potential pharmaceutical interactions, and enhancement of acute care pharmacological interventions. These professionals also facilitate interdisciplinary coordination and contribute to ensuring prompt, evidence-informed medication delivery during critical care scenarios. Multiple investigations have shown that pharmacist engagement enhances resuscitation processes, pharmaceutical precision, and compliance with established therapeutic guidelines, potentially yielding favorable patient outcomes. While research examining the direct correlation between pharmacist participation and mortality rates, morbidity indices, and hospitalization duration remains constrained, existing scholarship indicates that incorporating clinical pharmacists into emergency response and intensive care units strengthens comprehensive patient safety measures and promotes more effective cardiac arrest interventions [2].

TRAINING AND COMPETENCY REQUIREMENTS FOR CLINICAL PHARMACISTS DURING CARDIOPULMONARY RESUSCITATION

Advanced Cardiovascular Life Support and Basic Life Support Certification

ACLS and BLS credentials are essential for the professional development of clinical pharmacists participating in cardiopulmonary resuscitation and emergency medical teams. These educational initiatives strengthen the readiness of pharmacists to engage in critical and urgent resuscitation procedures through enhanced comprehension of standardized resuscitation protocols, emergency pharmaceutical administration, and collaborative communication during cardiac emergencies. ACLS and BLS credentials reinforce pharmacists' capacity to facilitate evidence-informed drug therapy, execute precise dosage confirmation, and provide meaningful contributions during urgent medical situations. Furthermore, continuous education, interprofessional training, and sustained clinical proficiency are fundamental to ensure ongoing professional advancement and effective integration of pharmacists within emergency and intensive care environments [54].

Simulation-Based and Mock Code Training

Educational simulations and mock code exercises serve crucial functions in equipping clinical pharmacists to engage in cardiopulmonary resuscitation and emergency response protocols. These pedagogical approaches offer pharmacists the opportunity to rehearse urgent medication preparation, dosage confirmation, and interpersonal communication competencies within high-intensity simulated settings. Engagement in mock code scenarios enhances pharmacists' self-assurance, familiarity with resuscitation procedures, and capacity to perform competently during actual cardiac arrest situations. Furthermore, simulation-based learning strengthens interprofessional teamwork and facilitates optimal coordination among healthcare practitioners involved in emergency interventions. Ongoing competency evaluation, professional development, and emergency readiness activities are vital for sustaining clinical preparedness and maximizing pharmacist effectiveness in resuscitation scenarios [54].

Emergency Preparedness and Interdisciplinary Collaboration

Emergency readiness and interprofessional cooperation are fundamental elements of successful cardiopulmonary resuscitation and emergency response coordination. Clinical pharmacists play a significant role in multidisciplinary resuscitation units through their contributions to pharmaceutical management, therapeutic decision-making processes, and communication in high-intensity cardiac arrest situations. Involvement in mock code scenarios, simulation-based training, and team-oriented emergency readiness initiatives strengthens pharmacists' capacity for effective collaboration with physicians, nursing staff, and additional healthcare practitioners during resuscitation interventions. Interprofessional education and routine preparedness instruction enhance communication, coordination, and the overall effectiveness of emergency response units. Reinforcing collaborative practice among healthcare professionals may lead to enhanced medication safety, compliance with resuscitation protocols, and superior patient care during critical emergencies [53, 54].

Continuing Education and Clinical Competency Development

Ongoing professional education and clinical competency advancement are fundamental for preserving the readiness of clinical pharmacists engaged in cardiopulmonary resuscitation and emergency care delivery. Sustained professional educational initiatives assist pharmacists in staying current with contemporary resuscitation guidelines, emergency pharmacotherapy, medication safety protocols, and critical care procedures. Routine competency evaluation and advanced clinical instruction enhance pharmacists' capacity to engage effectively in high-intensity resuscitation events and facilitate evidence-based therapeutic interventions. Additionally, interprofessional education and continuous professional advancement contribute to enhanced communication, clinical decision-making, and collaborative practice within emergency response units in the hospital. Preserving clinical competency through continuous instruction and preparedness activities is important for optimizing pharmacist performance and ensuring superior patient care during cardiac arrest management [54].

CHALLENGES AND LIMITATIONS OF CLINICAL PHARMACIST PARTICIPATION DURING CARDIOPULMONARY RESUSCITATION

Limited Availability of Clinical Pharmacists During Emergencies

Access to clinical pharmacists during urgent medical interventions and resuscitation procedures is a considerable obstacle in numerous healthcare facilities. Staffing limitations, inadequate emergency department support, and financial restrictions may impede the regular involvement of pharmacists in the cardiopulmonary resuscitation and intensive care teams. Many hospitals lack round-the-clock clinical pharmacy services, especially smaller medical facilities and resource-constrained organizations, potentially compromising prompt pharmaceutical assistance during critical emergencies. Furthermore, escalating clinical demands and conflicting professional obligations may constrain pharmacists' capacity to engage meaningfully in emergency response protocols. These barriers may result in inconsistent pharmacist engagement during cardiac arrest interventions and diminish opportunities for immediate medication assessment, dosage confirmation, and pharmacological guidance throughout resuscitation procedures [2].

Inadequate Training and Resource Constraints

Deficient educational preparation and restricted organizational resources may impede the meaningful engagement of clinical pharmacists in cardiopulmonary resuscitation and emergency intervention. Disparities in emergency care education, minimal exposure to simulation-based instruction, and inadequate opportunities for practice code participation may compromise pharmacists' assurance and proficiency during critical resuscitation scenarios. Within certain medical environments, resource limitations, including inadequate personnel, the absence of a formal educational curriculum, and restricted access to ongoing professional development, may additionally constrain the advancement of emergency readiness capabilities among pharmacists. Moreover, the lack of uniform competency evaluation protocols may result in inconsistent pharmacist performance in cardiac arrest interventions. Enhancing educational curricula, simulation training, and collaborative learning programs may facilitate improved pharmacist readiness and maximize engagement in emergency and intensive care [55].

Lack of Standardized Role Definition During Resuscitation

Although clinical pharmacists increasingly participate in emergency response and resuscitation teams, the absence of uniform role specifications during cardiopulmonary resuscitation constitutes a significant constraint on their participation. Pharmacists' duties during cardiac arrest interventions may differ substantially across healthcare organizations based on personnel availability, organizational protocols, and emergency pharmacy service accessibility. Within certain environments, pharmacists concentrate primarily on drug preparation and dosage validation, whereas in alternative settings, they may actively engage in clinical decision-making, record-keeping, and interprofessional communication during resuscitation scenarios. This inconsistency may result in workflow integration disparities, emergency response inefficiencies, and suboptimal utilization of pharmacists' clinical knowledge during critical circumstances. Developing uniform role specifications and evidence-informed practice guidelines may enhance consistency, facilitate interprofessional cooperation, and strengthen the overall impact of pharmacists' involvement in resuscitation interventions [52].

Limited Evidence on Long-Term Clinical Outcomes

While numerous investigations have shown the positive influence of clinical pharmacist engagement in cardiopulmonary resuscitation procedures, data concerning extended clinical outcomes remain insufficient. Most available research predominantly examines process-oriented outcomes, including medication error mitigation, enhanced ACLS protocol compliance, and optimized pharmaceutical administration during emergency interventions. However, the direct influence of pharmacist participation on extended patient outcomes, including mortality rates, neurological rehabilitation, morbidity levels, and hospitalization duration, has not been comprehensively established. Furthermore, numerous current investigations employ observational methodologies with relatively limited sample

populations, potentially restricting the applicability of the results across various healthcare environments. Additional comprehensive multi-institutional research is required to assess the extended clinical and economic implications of incorporating clinical pharmacists into cardiopulmonary resuscitation and intensive care teams [52].

FUTURE PERSPECTIVE

Expansion of Clinical Pharmacist Roles

Broadening clinical pharmacist engagement in emergencies and intensive care services can strengthen interdisciplinary cooperation and enhance pharmaceutical decision-making during cardiac arrest interventions. Greater involvement of pharmacists in emergency response teams, rapid intervention systems, and post-arrest care could further reinforce their contributions to patient safety and resuscitation excellence [2].

Technology and Simulation-Based Training

Developments in simulation-based instruction, digital learning environments, and emergency training programs can enhance pharmacists' emergency readiness and competence during cardiopulmonary resuscitation. Technology-enhanced education can also facilitate continuous competency evaluation and interdisciplinary communication throughout emergency response preparation [2].

Standardized Practice Frameworks

Establishing standardized clinical practice protocols and clearly articulated pharmacist duties during resuscitation scenarios could enhance the consistency of workflow incorporation, pharmaceutical management, and emergency response effectiveness in healthcare facilities [54].

Future Research Directions

Supplementary, comprehensive, and multi-institutional investigations are necessary to assess the extended influence of pharmacist involvement on mortality rates, neurological rehabilitation, healthcare expenditures, and overall patient outcomes after cardiac arrest intervention [55].

CONCLUSION

Clinical pharmacists assume a progressively significant function in cardiopulmonary resuscitation and post-arrest management through their involvement in pharmaceutical preparation, dosage confirmation, pharmacotherapeutic decision-making, and compliance with ACLS protocols. Their active engagement in emergency response and interdisciplinary resuscitation teams has been correlated with enhanced pharmaceutical safety, optimization of time-sensitive treatments, reduction in medication-associated errors, and improved coordination during high-intensity cardiac arrest scenarios. Additionally, clinical pharmacists provide substantial contributions to post-resuscitation care through pharmaceutical monitoring, therapeutic optimization, and support of evidence-based intensive care management. Despite increasing acknowledgment of their function, obstacles, including insufficient staffing, training variability, absence of standardized role specifications, and limited evidence concerning extended clinical outcomes, persist in affecting pharmacist integration into emergency and intensive care services. Reinforcing emergency medicine educational programs, simulation-based instruction, and interdisciplinary cooperation could further improve pharmacist readiness and resuscitation effectiveness. Prospective research emphasizing extended clinical and economic outcomes will be crucial for better defining and expanding clinical pharmacist roles in cardiopulmonary resuscitation and emergency care practice.

REFERENCES

1. Clinical Pharmacist Services in the Emergency Department. *Ann Emerg Med.* 2015 Oct;66(4):444-5. doi: 10.1016/j.annemergmed.2015.07.513. PMID: 26398179.

2. Patel H, Wee M, Tejani AM, Lau A. Clinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review. *Pharmacy (Basel)*. 2025 Jun 24;13(4):89. doi: 10.3390/pharmacy13040089. PMID: 40700260; PMCID: PMC12286068.
3. Eppert HD, Reznick AJ. ASHP guidelines on emergency medicine pharmacist services. *Am J Health Syst Pharm*. 2011;68:e81–e95.
4. Farmer BM, Hayes BD, Rao R, Farrell N, Nelson L. The role of clinical pharmacists in the emergency department. *J Med Toxicol*. 2018;14(1):114–116. doi:10.1007/s13181-017-0634-4. Epub 2017 Oct 26. PubMed: 29075954. PubMed Central: PMC6013729.
5. Morgan SR, Acquisto NM, Coralic Z, Basalyga V, Campbell M, Kelly JJ, Langkiet K, Pearson C, Sokn E, Phelan M. Clinical pharmacy services in the emergency department. *Am J Emerg Med*. 2018 Oct;36(10):1727–1732. doi: 10.1016/j.ajem.2018.01.056. Epub 2018 Jan 31. PMID: 29475633.
6. Punj E, Collins A, Agravedi N, Marriott J, Sapey E. What is the evidence that a pharmacy team working in an acute or emergency medicine department improves outcomes for patients: A systematic review. *Pharmacol Res Perspect*. 2022;10(5):e01007. doi:10.1002/prp2.1007. PubMed: 36102210.
7. Bolt J, Semchuk W, Loewen P, Bell A, Strugari C. A Canadian survey of pharmacist participation during cardiopulmonary resuscitation. *Can J Hosp Pharm*. 2015;68(4):290–295. doi:10.4212/cjhp.v68i4.1468. PubMed: 26327702.
8. Draper HM, Eppert JA. Association of pharmacist presence on compliance with advanced cardiac life support guidelines during in-hospital cardiac arrest. *Ann Pharmacother*. 2008;42(4):469–474. doi:10.1345/aph.1K475. PubMed: 18349308.
9. Bingham AL, Kavelak HL, Hollands JM, Finn LA, Delic JJ, Schroeder N, et al. Advanced cardiac life support certification for student pharmacists improves simulated patient survival. *Curr Pharm Teach Learn*. 2020;12(8):975–980. doi:10.1016/j.cptl.2020.04.002. PubMed: 32565000.
10. Scarponcini TR, Edwards CJ, Rudis MI, Jasiak KD, Hays DP. The role of the emergency pharmacist in trauma resuscitation. *J Pharm Pract*. 2011;24(2):146–159. doi:10.1177/0897190011400550. PubMed: 21712210.
11. Patanwala AE, Hays DP. Pharmacist's activities on a trauma response team in the emergency department. *Am J Health Syst Pharm*. 2010;67(18):1536–1538. doi:10.2146/ajhp090311. PubMed: 20811031.
12. Montgomery K, Hall AB, Keriases G. Pharmacist's impact on acute pain management during trauma resuscitation. *J Trauma Nurs*. 2015;22(2):87–90. doi:10.1097/JTN.0000000000000112. PubMed: 25768964.
13. McGinnis C, Kim C, Qureshi A, Scholle C, Ramanan R. Evaluation and perception of clinical pharmacist participation in a rapid response team during cardiopulmonary resuscitation. *Qual Manag Health Care*. 2022;31(1):34–37. doi:10.1097/QMH.0000000000000325. PubMed: 34694255.
14. Currey EM, Falconer N, Isoardi KZ, Barras M. Impact of pharmacists during in-hospital resuscitation or medical emergency response events: A systematic review. *Am J Emerg Med*. 2024;75:98–110. doi:10.1016/j.ajem.2023.10.020. Epub 2023 Oct 22. PubMed: 37939522.
15. Roman C, Dooley M, Fitzgerald M, Smit V, Cameron P, Mitra B. Pharmacists in trauma: A randomised controlled trial of emergency medicine pharmacists in trauma response teams. *Emerg Med J*. 2024;41(7):397–403. doi:10.1136/emmermed-2022-212934. PubMed: 38749667.
16. Holmberg MJ, Ross CE, Fitzmaurice GM, Chan PS, Duval-Arnould J, Grossestreuer AV, et al. Annual incidence of adult and pediatric in-hospital cardiac arrest in the United States. *Circ Cardiovasc Qual Outcomes*. 2019;12(7):e005580. PMID: 31545574.
17. Martin SS, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. 2024 heart disease and stroke statistics: A report of US and global data from the American Heart Association. *Circulation*. 2024;149(8):e347–e913. doi:10.1161/CIR.0000000000001209. PMID: 38264914.
18. Girotra S, Nallamothu BK, Spertus JA, Li Y, Krumholz HM, Chan PS, et al. Trends in survival after in-hospital cardiac arrest. *N Engl J Med*. 2012;367(20):1912–1920. doi:10.1056/NEJMoa1109148. PMID: 23150959.

19. Wiberg S, Holmberg MJ, Donnino MW, Kjaergaard J, Hassager C, Witten L, et al. Age-dependent trends in survival after adult in-hospital cardiac arrest. *Resuscitation*. 2020;151:189–196. doi:10.1016/j.resuscitation.2020.03.008. PMID: 32246986.
20. Sandroni C, Nolan J, Cavallaro F, Antonelli M. In-hospital cardiac arrest: Incidence, prognosis and possible measures to improve survival. *Intensive Care Med*. 2007;33(2):237–245. doi:10.1007/s00134-006-0326-z. PMID: 17019558.
21. Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics—2018 update: A report from the American Heart Association. *Circulation*. 2018;137(12):e67–e492. doi:10.1161/CIR.0000000000000558. PMID: 29386200.
22. Cagino LM, Moskowitz A, Nallamothu BK, McSparron J, Iwashyna TJ, Get With The Guidelines-Resuscitation Investigators. Trends in return of spontaneous circulation and survival to hospital discharge for in-intensive care unit cardiac arrests. *Ann Am Thorac Soc*. 2023;20(7):1012–1019. doi:10.1513/AnnalsATS.202205-393OC. PMID: 36939838.
23. Andersen LW, Holmberg MJ, Berg KM, Donnino MW, Granfeldt A. In-hospital cardiac arrest: A review. *JAMA*. 2019;321(12):1200–1210. doi:10.1001/jama.2019.1696. PMID: 30912843.
24. Merchant RM, Becker LB, Brooks SC, Chan PS, Del Rios M, McBride ME, et al. The American Heart Association emergency cardiovascular care 2030 impact goals and call to action to improve cardiac arrest outcomes: A scientific statement from the American Heart Association. *Circulation*. 2024;149(8):e914–e933. doi:10.1161/CIR.0000000000001196. PMID: 38250800.
25. Khera R, Tang Y, Link MS, Krumholz HM, Girotra S, Chan PS. Association between hospital recognition for resuscitation guideline adherence and rates of survival for in-hospital cardiac arrest. *Circ Cardiovasc Qual Outcomes*. 2019;12(3):e005429. doi:10.1161/CIRCOUTCOMES.118.005429. PMID: 30871337.
26. Roessler LL, Holmberg MJ, Pawar RD, Lassen AT, Moskowitz A, Get With The Guidelines-Resuscitation Investigators. Resuscitation quality in the ICU: A retrospective analysis. *Chest*. 2022;162(3):569–577. doi:10.1016/j.chest.2022.03.015. PMID: 35305970.
27. Kim JY, Hwang SO, Shin SD, Yang HJ, Chung SP, Lee SW, et al. Korean Cardiac Arrest Research Consortium (KoCARC): Rationale, development, and implementation. *Clin Exp Emerg Med*. 2018;5(3):165–176. doi:10.15441/ceem.17.259. PMID: 30269452.
28. Ro YS, Shin SD, Song KJ, Lee EJ, Kim JY, Ahn KO, et al. A trend in epidemiology and outcomes of out-of-hospital cardiac arrest by urbanization level: A nationwide observational study from 2006 to 2010 in South Korea. *Resuscitation*. 2013;84(5):547–557. doi:10.1016/j.resuscitation.2012.12.020. PMID: 23313428.
29. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication. A scientific statement from the International Liaison Committee on Resuscitation. *Resuscitation*. 2008;79:350–379. doi:10.1016/j.resuscitation.2008.09.017. PMID: 18963350.
30. Kim JH, Oh YM, So BH, Hong TY, Lee WJ, Choi SP, Park KN. Systemic complications in comatose survivors following cardiopulmonary resuscitation. *J Korean Soc Emerg Med*. 2008;19(1):88–93.
31. Lee BY, Hong SB. Rapid response systems in Korea. *Acute Crit Care*. 2019;34:108–116. doi:10.4266/acc.2019.00535. PMID: 31723915.
32. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Böttiger BW, Callaway C, et al. Post-cardiac arrest syndrome: Epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation and affiliated organizations. *Circulation*. 2008;118:2452–2483. doi:10.1161/CIRCULATIONAHA.108.190652. PMID: 18948368.
33. Opie LH. Reperfusion injury and its pharmacologic modification. *Circulation*. 1989;80(4):1049–1062. doi:10.1161/01.CIR.80.4.1049. PMID: 2571429.
34. White BC, Grossman LI, Krause GS. Brain injury by global ischemia and reperfusion: A theoretical perspective on membrane damage and repair. *Neurology*. 1993;43(9):1656–1665. doi:10.1212/WNL.43.9.1656. PMID: 8414008.

35. Neumar RW. Molecular mechanisms of ischemic neuronal injury. *Ann Emerg Med*. 2000;36(5):483–506. doi:10.1067/mem.2000.110995. PMID: 11054204.
36. Yao Y, Johnson NJ, Perman SM, Ramjee V, Grossestreuer AV, Gaieski DF. Myocardial dysfunction after out-of-hospital cardiac arrest: Predictors and prognostic implications. *Intern Emerg Med*. 2018;13(5):765–772. doi:10.1007/s11739-017-1756-z. PMID: 28983759.
37. Ray L, Acquisto NM, Coralic Z, Feldman R, Mercer K, Zimmerman DE, et al. A national survey of medication utilization for cardiac resuscitation in the emergency department: A survey of emergency medicine pharmacists. *Am J Health Syst Pharm*. 2024;81(24):1313–1321. doi:10.1093/ajhp/zxae186. PMID: 38990863.
38. Robb C, Douglas N, McKechnie E, Upton D. Evaluation of the role of pharmacists in a cardiac arrest team. *Hosp Pharm*. 2003;10(1):22–24.
39. Lamkin L, Lindsey S, Weant K, Shoff H, Pinkston C. Implications of the presence of an emergency medicine pharmacist during critical care trauma patient resuscitation. *J Am Coll Clin Pharm*. 2019;2(3):251–256. doi:10.1002/jac5.1068.
40. Fairbanks RJ. Results of the emergency pharmacist outcomes study. In: *Proceedings of the ASHP Mid-Year Clinical Meeting*; Las Vegas, NV, USA. 2007 Dec 5. Rochester (NY): University of Rochester School of Medicine; 2007.
41. Lada P, Delgado G Jr. Documentation of pharmacists' interventions in an emergency department and associated cost avoidance. *Am J Health Syst Pharm*. 2007;64(1):63–68. doi:10.2146/ajhp050213. PMID:17189582.
42. Machado C, Barlows TG III, Marsh WA, Coto-Depani Y, Dalin G. Pharmacists on the emergency cardiopulmonary resuscitation team: Their responsibilities, training, and attitudes. *Hosp Pharm*. 2003;38(1):40–49. doi:10.1177/001857870303800113.
43. Roddy M, Fowler C. Optimization of pediatric medical emergency training (PedMET) program for pharmacists in the inpatient setting. *J Pediatr Pharmacol Ther*. 2024;29(4):417–424. doi:10.5863/1551-6776-29.4.417. PMID:39144395.
44. Levy B, Perez P, Perny J, Thivillier C, Gerard A. Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. *Crit Care Med*. 2011;39(3):450–455. doi:10.1097/CCM.0b013e3181ffe0eb. PMID:21037469.
45. Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Dispensing and administration – 2008. *Am J Health Syst Pharm*. 2009;66(10):926–946. doi:10.2146/ajhp080715. PMID:19420311.
46. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. *Pharmacotherapy*. 1999;19(5):556–564. doi:10.1592/phco.19.8.556.31531. PMID:10331818.
47. Bond CA, Raehl CL. Adverse drug reactions in United States hospitals. *Pharmacotherapy*. 2006;26(5):601–608. doi:10.1592/phco.26.5.601. PMID:16637789.
48. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. *Pharmacotherapy*. 2007;27(4):481–493. doi:10.1592/phco.27.4.481. PMID:17381374.
49. Ortmann MJ, Johnson EG, Jarrell DH, Bilhimer M, Hayes BD, Mishler A, Pugliese RS, Roberson TA, Slocum G, Smith AP, Yabut K, Zimmerman DE. ASHP guidelines on emergency medicine pharmacist services. *Am J Health Syst Pharm*. 2021;78(3):261–275. doi:10.1093/ajhp/zxaa378. PMID:33480409.
50. Tully MP, Seston EM. Impact of pharmacists providing a prescription review and monitoring service in ambulatory care or community practice. *Ann Pharmacother*. 2000;34(11):1320–1331. doi:10.1345/aph.19374. PMID:11098348.
51. Coast-Senior EA, Kroner BA, Kelley CL, Trilli LE. Management of patients with type 2 diabetes by pharmacists in primary care clinics. *Ann Pharmacother*. 1998;32(6):636–641. doi:10.1345/aph.17095. PMID:9640480.
52. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: A systematic review. *Arch Intern Med*. 2006;166(9):955–964. doi:10.1001/archinte.166.9.955. PMID:16682568.

-
53. Chisholm-Burns MA, Graff Zivin JS, Lee JK, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, Abraham I, Palmer J. Economic effects of pharmacists on health outcomes in the United States: A systematic review. *Am J Health Syst Pharm*. 2010;67(19):1624–1634. doi:10.2146/ajhp100077. PMID:20852164.
 54. Skains RM, Hayes JM, Selman K, Zhang Y, Thatphet P, Toda K, et al. Emergency department programs to support medication safety in older adults: A systematic review and meta-analysis. *JAMA Netw Open*. 2025;8:e250814. doi:10.1001/jamanetworkopen.2025.0814.
 55. Brandner O, Campisi L, Nguyen AL. Pediatric pharmacists' participation in cardiopulmonary resuscitation events. *J Pediatr Pharmacol Ther*. 2025;30(4):520–525. doi:10.5863/JPPT25-00045. PMID:40821421.